Physician profile
Caitlyn Ryan
NPI 1356921308
$1,333.30
in general payments reported to CMS, 2019-2025
24 companies · $45.87 in 2025
The $45.87 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $575 · 2023: $713 · 2025: $45.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.58 |
| Education | $219.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $229.52 | 2022-2023 | Retevmo |
| Seagen INC. | $209.71 | 2022-2023 | Adcetris, Tivdak, Padcev |
| Incyte Corporation | $153.85 | 2022-2023 | Jakafi |
| Celgene Corporation | $107.20 | 2022-2023 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $69.99 | 2023 | Erleada |
| Abbvie INC. | $63.75 | 2022-2025 | |
| Daiichi Sankyo INC. | $50.59 | 2022-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $49.92 | 2022-2023 | Lynparza, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $42.60 | 2022-2023 | Iclusig |
| Regeneron Healthcare Solutions, INC. | $36.26 | 2022-2023 | Libtayo |
| Sobi, INC | $35.61 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $34.35 | 2022-2023 | Opdivo |
| Ascendis Pharma Endocrinology INC | $27.49 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $26.25 | 2025 | Rexulti |
| Pharmacyclics LLC, An Abbvie Company | $24.99 | 2023 | Imbruvica, Epkinly |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.94 | 2022 | |
| Deciphera Pharmaceuticals INC. | $24.14 | 2022 | |
| Servier Pharmaceuticals LLC | $23.21 | 2022 | |
| Puma Biotechnology, INC. | $22.51 | 2022 | |
| Astellas Pharma US INC | $18.33 | 2023 | Xospata |
| Foundation Medicine, INC. | $15.70 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.93 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.